Consolidated Statements of Changes in Stockholders’ Equity - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total Citius Pharmaceuticals, Inc. Shareholder’s Equity	Non-Controlling Interest	Total
Balance at Oct. 01, 2020		$ 55,577	$ 104,208,958	$ (70,593,867)	$ 33,670,668		$ 33,670,668
Balance (in Shares) at Oct. 01, 2020		55,576,996
Issuance of NoveCite common stock			1,799,640	(2,399,520)	(599,880)	$ 600,380	500
Issuance of common stock in private placement offering, net of costs of $1,549,602		$ 15,456	18,434,954		18,450,410		18,450,410
Issuance of common stock in private placement offering, net of costs of $1,549,602 (in Shares)		15,455,960
Issuance of common stock in registered direct offering, net of costs of $5,520,160		$ 50,830	70,929,012		70,979,842		70,979,842
Issuance of common stock in registered direct offering, net of costs of $5,520,160 (in Shares)		50,830,566
Issuance of common stock upon exercise of warrants		$ 23,996	31,106,138		31,130,134		31,130,134
Issuance of common stock upon exercise of warrants (in Shares)		23,995,907
Issuance of common stock for services		$ 50	67,950		68,000		68,000
Issuance of common stock for services (in Shares)		50,000
Issuance of common stock upon exercise of stock options		$ 70	82,564		82,634		82,634
Issuance of common stock upon exercise of stock options (in Shares)		70,000
Stock-based compensation expense			1,454,979		1,454,979		1,454,979
Net loss				(23,054,434)	(23,054,434)		(23,054,434)
Balance at Sep. 30, 2021		$ 145,979	228,084,195	(96,047,821)	132,182,353	600,380	132,782,733
Balance (in Shares) at Sep. 30, 2021		145,979,429
Issuance of common stock for services		$ 232	377,972		378,204		378,204
Issuance of common stock for services (in Shares)		231,701
Stock-based compensation expense			3,905,954		3,905,954		3,905,954
Net loss				(33,640,646)	(33,640,646)		(33,640,646)
Balance at Sep. 30, 2022		$ 146,211	$ 232,368,121	$ (129,688,467)	$ 102,825,865	$ 600,380	$ 103,426,245
Balance (in Shares) at Sep. 30, 2022		146,211,130